Compare Pfizer Inc (PFE) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Thomson Reuters Corp — how do they compare? Pfizer Inc trades at $27.91 (market cap $158.39B), while Thomson Reuters Corp trades at $96.77 (market cap $42.75B). The key difference: Pfizer Inc is far larger — about 3.7× Thomson Reuters Corp's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | TRI | |
|---|---|---|
Market Cap | $158.39B | $42.75B |
Volume | 29,869,932 | — |
Sector | Health | Industrials |
52-Week High | $29.02 | $175.65 |
52-Week Low | $23.60 | $76.55 |
Enterprise Value | $209.89B | $45.37B |
Dividend Yield | 6.19% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.45, down 1.25% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.77, beating expectations, and maintains a solid gross profit margin of 73.18%. Recent news highlights pipeline advancements in obesity and oncology, with a dividend of $0.43 scheduled for payment in September 2026.
The outlook for Pfizer is mixed; analyst consensus is a 'Hold' with a $28.33 price target, citing patent cliff concerns but recognizing defensive cash flow. Key risks include declining net income margins projected for 2026 and high debt levels. Upside potential hinges on successful drug pipeline execution and cost management amid competitive pressures.
Thomson Reuters (TRI) trades at $98.81, down 6.5% over 24 hours but maintains strong fundamentals with 21.22% net margins and 13.97% ROE. The stock shows bullish technical signals with support at $99 and resistance at $109, while recent Q2 earnings beat expectations with $0.99 EPS versus $0.96 estimates. AI expansion initiatives and recurring revenue growth (82% of total) support momentum, though a recent cybersecurity incident involving court case management systems presents operational risks.
Outlook remains positive with analyst consensus at $104.50 (51.85% buy ratings), driven by organic revenue growth and cost-efficient AI model development. Key risks include cybersecurity vulnerabilities and potential margin pressure from increased technology investments. The current valuation at 27.84 P/E appears reasonable given sustained profitability and market leadership in legal and tax content services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
